Resistance to Imatinib: Mutations and Beyond

Seminars in Hematology

Volumn 47, Issue 4, 2010, Pages 335-343

  La Rosée, Paul ^a   Deininger, Michael W ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; DASATINIB; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; OCTAMER TRANSCRIPTION FACTOR 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; CANCER STEM CELL; CELL RENEWAL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; GENE ACTIVATION; GENE MUTATION; HUMAN; LEUKEMIA CELL; LEUKEMIA REMISSION; NONHUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENOTYPE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 77957041354     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.06.005     Document Type: Article

References (71)

1. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
2. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007, 7:345-356.
3. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
4. Hochhaus A., O'Brien S.G., Guilhot F., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
5. Hochhaus A., Druker B., Sawyers C., et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008, 111:1039-1043.
6. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
7. Mahon F.X., Rea D., Guilhot F., et al. Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients. Blood 2009, 114:353a.
8. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
9. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
10. La Rosee P., Holm-Eriksen S., Konig H., et al. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica 2008, 93:765-769.
11. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289:1938-1942.
12. Wisniewski D., Lambek C.L., Liu C., et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002, 62:4244-4255.
13. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
14. Laneuville P., DiLea C., Yin O.Q., Woodman R.C., Mestan J., Manley P.W. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J Clin Oncol 2010, 28:e169-e171.
15. Muller M.C., Cortes J.E., Kim D.W., et al. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009, 114:4944-4953.
16. Hughes T., Saglio G., Branford S., et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009, 27:4204-4210.
17. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
18. Jabbour E., Hochhaus A., Cortes J., La Rosee P., Kantarjian H.M. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2010, 24:6-12.
19. Soverini S., Gnani A., Colarossi S., et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009, 114:2168-2171.
20. Shah N.P., Skaggs B.J., Branford S., et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007, 117:2562-2569.
21. O'Hare T., Shakespeare W.C., Zhu X., et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
22. Nagar B., Bornmann W.G., Pellicena P., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002, 62:4236-4243.
23. Azam M., Seeliger M.A., Gray N.S., Kuriyan J., Daley G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008, 15:1109-1118.
24. Skaggs B.J., Gorre M.E., Ryvkin A., et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A 2006, 103:19466-19471.
25. Griswold I.J., MacPartlin M., Bumm T., et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006, 26:6082-6093.
26. Nicolini F.E., Mauro M.J., Martinelli G., et al. Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation. Blood 2009, 114:5271-5278.
27. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
28. Stoklosa T., Poplawski T., Koptyra M., et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008, 68:2576-2580.
29. Koptyra M., Cramer K., Slupianek A., Richardson C., Skorski T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 2008, 22:1969-1972.
30. Fernandes M.S., Reddy M.M., Gonneville J.R., et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009, 114:1813-1819.
31. Chu S., Holtz M., Gupta M., Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004, 103:3167-3174.
32. Copland M., Hamilton A., Elrick L.J., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107:4532-4539.
33. Konig H., Copland M., Chu S., Jove R., Holyoake T.L., Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008, 68:9624-9633.
34. Konig H., Holyoake T.L., Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008, 111:2329-2338.
35. Konig H., Holtz M., Modi H., et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008, 22:748-755.
36. Chu S., Xu H., Shah N.P., et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005, 105:2093-2098.
37. Jiang X., Zhao Y., Smith C., et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007, 21:926-935.
38. Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
39. La Rosée P., Shen L., Stoffregen E.P., Deininger M., Druker B.J. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). Hematol J 2003, 4:413-419.
40. Jamieson C.H. Chronic myeloid leukemia stem cells. Hematol Am Soc Hematol Educ Program 2008, 436-442.
41. Burchert A., Wang Y., Cai D., et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005, 19:1774-1782.
42. Wang Y., Cai D., Brendel C., et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 2007, 109:2147-2155.
43. Weisberg E., Wright R.D., McMillin D.W., et al. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 2008, 7:1121-1129.
44. Mackenzie R., Snead J., VanDyke J., Deininger M.W. Defining extrinsic survival pathways in CML progenitor cells. Blood 2009, 114:388a.
45. Lemoli R.M., Salvestrini V., Bianchi E., et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood 2009, 114:5191-5200.
46. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351:657-667.
47. Abrahamsson A.E., Geron I., Gotlib J., et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A 2009, 106:3925-3929.
48. Coluccia A.M., Vacca A., Dunach M., et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007, 26:1456-1466.
49. Zhao C., Blum J., Chen A., et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12:528-541.
50. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
51. Dierks C., Beigi R., Guo G.R., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14:238-249.
52. Essers M.A., Offner S., Blanco-Bose W.E., et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908.
53. Crossman L.C., Mori M., Hsieh Y.C., et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 2005, 90:459-464.
54. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794-2799.
55. McWeeney S.K., Pemberton L.C., Loriaux M.M., et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic phase chronic myeloid leukemia patients treated with imatinib. Blood 2010, 115:315-325.
56. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8:1018-1029.
57. Dulucq S., Bouchet S., Turcq B., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008, 112:2024-2027.
58. Kim D.H., Sriharsha L., Xu W., et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009, 15:4750-4758.
59. Hatziieremia S., Jordanides N.E., Holyoake T.L., Mountford J.C., Jorgensen H.G. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34(+) cells to imatinib. Exp Hematol 2009, 37:692-700.
60. Shah N.P., Kantarjian H.M., Kim D.W., et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008, 26:3204-3212.
61. Shah N.P., Kasap C., Weier C., et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008, 14:485-493.
62. Snead J.L., O'Hare T., Adrian L.T., et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009, 114:3459-3463.
63. Hiwase D.K., White D.L., Saunders V.A., Kumar S., Melo J.V., Hughes T.P. Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells. Leukemia 2009, 23:1205-1206.
64. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
65. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
66. Wu E.Q., Johnson S., Beaulieu N., et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010, 26:61-69.
67. Noens L., van Lierde M.A., de Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
68. Rosti G., Palandri F., Castagnetti F., et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009, 114:4933-4938.
69. Cortes J.E., Jones D., O'Brien S., et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2009, 28:398-404.
70. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the International Randomized Phase III ENESTnd Trial. Blood 2009, 114, LBA-1. http://ash.confex.com/ash/2009/webprogram/Session2309.html.
71. O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.